GlycoMimetics is a clinical-stage biotechnology company focused on improving the lives of people living with cancer and inflammatory diseases by utilizing the inhibition of carbohydrate interactions that occur on the surface of cells. Co. is developing uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, a hematologic cancer, and potentially other hematologic cancers. Co. has designed an antagonist of E-selectin, GMI-1687, that could be suitable for subcutaneous administration. Co. has also selected a primary galectin drug candidate, GMI-2093, for evaluation in preclinical studies. The GLYC YTD return is shown above.
The YTD Return on the GLYC YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether GLYC YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GLYC YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|